Schizophrenia/Psychosis

This study is the first to assess the efficacy of this drug combination in a real-world setting.

What is the risk of diabetes, hypertension, or hyperlipidemia with antipsychotic polypharmacy in patients with schizophrenia? Researchers investigated these associations in a population-based prospective cohort study.

Get ready for our upcoming virtual, interactive conference with some highlights from 2022.

The experts weighed in on a wide variety of psychiatric issues for the September 2023 issue of Psychiatric Times.

From connections between cannabis use and schizophrenia to some non-psychiatric medications that may worsen symptoms of major depression, here are highlights from the week in Psychiatric Times.

Here are some updates from the world of psychiatry throughout the month of September.

The treatment, if approved, “will represent the first novel pharmacological approach to treating schizophrenia in several decades and provide a new treatment option for patients and their physicians.”

A look at the association between cannabis use and schizophrenia, as well as the need for comprehensive public health policies and education.

Here’s what the historic case of the Genain quadruplets reveals about some deeper, uncomfortable truths about American society.

The presentation of schizophrenia differs significantly between men and women. Here's what you need to know.

What is new in research on psychiatric care for Latinx patient populations?

An expert discusses recent research evaluating a selective M4 positive allosteric modulator for the treatment of schizophrenia.

Christoph Correll, MD, shares more on paliperidone palmitate 6-month for the treatment of schizophrenia.

These 3 posters covered the efficacy and safety of paliperidone palmitate in patients with schizophrenia.

From cannabis use disorder and schizophrenia to social media use and youth mental health, here are highlights from the week in Psychiatric Times.

Exploring the connection between trauma and the etiology of schizophrenia, and the ways this connection was historically interpreted in the case of the Genain quadruplets.

What is the association between cannabis use disorders and schizophrenia? Researchers used a nationwide register-based cohort study to investigate these associations.

From new research on psilocybin as a treatment for MDD to new FDA approvals for ADHD and BED, here are highlights from the week in Psychiatric Times.

“The Genain quadruplets have really gone down in psychiatric history for being the ‘poster girls’ for psychiatric genetics.”

Explore the complex interaction of cannabis and psychosis, and the sociocultural stressors and resulting neurobehavioral symptoms.

Report reviews key study results and provides updates on additional studies in development.

Awais Aftab, MD, and author Audrey Clare Farley, PhD, discuss Girls and Their Monsters: The Genain Quadruplets and the Making of Madness in America.

Awais Aftab, MD, interviews Audrey Clare Farley, PhD, author of Girls and Their Monsters: The Genain Quadruplets and the Making of Madness in America.

According to recent research, sleep problems were a common symptom in a large study of patients with first-episode psychosis.

From overutilization of emergency departments to reversible clomiphene-associated manic episodes, here are highlights from the week in Psychiatric Times.